keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane/tazobactam

keyword
https://www.readbyqxmd.com/read/28923865/an-in-vitro-comparison-of-ceftolozane-tazobactam-compared-to-traditional-beta-lactams-as-an-alternative-to-combination-antimicrobial-therapy-for-pseudomonas-aeruginosa
#1
Kellie J Goodlet, David P Nicolau, Michael D Nailor
Background: Guidelines for sepsis, febrile neutropenia, and hospital-acquired pneumonia include empiric regimens incorporating two antibiotics from different classes with activity against Pseudomonas aeruginosa for select at-risk patients to increase the likelihood of susceptibility to at least one agent.Objectives: The activity and cross-resistance rates of ceftolozane/tazobactam were compared to β-lactam comparators cefepime, ceftazidime, piperacillin/tazobactam, and meropenem alone and cumulatively with ciprofloxacin or tobramycin against P...
September 18, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28893779/pharmacokinetics-and-tissue-penetration-of-ceftolozane-tazobactam-in-diabetic-patients-with-lower-limb-infections-and-healthy-adult-volunteers
#2
Marguerite L Monogue, Sean M Stainton, Arlinda Baummer-Carr, Ashley K Shepard, James F Nugent, Joseph L Kuti, David P Nicolau
Ceftolozane/tazobactam displays potent activity against gram-negative bacteria that can cause diabetic foot infections (DFI), making it an attractive treatment option when few alternatives exist. The pharmacokinetics and tissue penetration of ceftolozane/tazobactam 1.5g q8h in patients (n=10) with DFI were compared with healthy volunteers (n=6) using in vivo microdialysis. In patient participants, median (range) total plasma pharmacokinetics for ceftolozane were Cmax: 55.2 (40.9-169.3) μg/mL, half-life (T1/2): 3...
September 11, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28893690/new-agents-for-the-treatment-of-infections-with-gram-negative-bacteria-restoring-the-miracle-or-false-dawn
#3
REVIEW
Hugh Wright, Robert A Bonomo, David L Paterson
BACKGROUND: Antibiotic resistance in gram-negative resistance has developed without a commensurate response in the successful development of antibiotic agents, though recent progress has been made. AIMS: This review aims to provide a summary of the existing evidence on efficacy, spectrum of activity and the development of resistance of new agents that have been licensed or completed advanced clinical trials that possess activity against resistant gram-negative organisms...
September 8, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28882013/antimicrobial-management-in-nosocomial-peritonitis-microbiota-drug-and-time
#4
REVIEW
A Montero, P Salgado Aranda, F Gilsanz, E Maseda
Complicated intra-abdominal infection requires surgical treatment and broad-spectrum empiric antibiotic treatment used early. The rapid spread of multidrug-resistant bacteria has become a serious threat, especially in critical care units. The excessive use of carbapenems has led to carbapenemase-producing Enterobacteriaceae, leaving tigecycline and colistin as therapeutical options. The new antimicrobials, ceftazidime-avibactam and ceftolozane-tazobactam open new horizons in the treatment of multi-drug resistant Enterobacteriaceae...
September 2017: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/28874376/genomics-and-susceptibility-profiles-of-extensively-drug-resistant-xdr-pseudomonas-aeruginosa-from-spain
#5
Ester Del Barrio-Tofiño, Carla López-Causapé, Gabriel Cabot, Alba Rivera, Natividad Benito, Concepción Segura, María Milagro Montero, Luisa Sorlí, Fe Tubau, Silvia Gómez-Zorrilla, Nuria Tormo, Raquel Durá-Navarro, Esther Viedma, Elena Resino-Foz, Marta Fernández-Martínez, Claudia González-Rico, Izaskun Alejo-Cancho, Jose Antonio Martínez, Cristina Labayru-Echverria, Carlos Dueñas, Ignacio Ayestarán, Laura Zamorano, Luis Martinez-Martinez, Juan Pablo Horcajada, Antonio Oliver
This study assessed the molecular epidemiology, resistance mechanisms and susceptibility profiles of a collection of 150 XDR P. aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane/tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (>95%) of the isolates were nonsusceptible to piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane/tazobactam (31%), amikacin (7%) and colistin (2%)...
September 5, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28815897/multidrug-resistant-enterobacteriaceae-pseudomonas-aeruginosa-and-vancomycin-resistant-enterococci-three-major-threats-to-hematopoietic-stem-cell-transplant-recipients
#6
REVIEW
Michael J Satlin, Thomas J Walsh
Hematopoietic stem cell transplant (HSCT) recipients are uniquely threatened by the emergence of multidrug-resistant (MDR) bacteria because these patients rely on immediate active antimicrobial therapy to combat bacterial infections. This review describes the epidemiology and treatment considerations for three challenging MDR bacterial pathogens in HSCT recipients: MDR Enterobacteriaceae, including extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus (VRE)...
August 16, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28803496/management-of-multidrug-resistant-pseudomonas-aeruginosa-in-the-intensive-care-unit-state-of-the-art
#7
Alberto Enrico Maraolo, Marco Cascella, Silvia Corcione, Arturo Cuomo, Salvatore Nappa, Guglielmo Borgia, Francesco Giuseppe De Rosa, Ivan Gentile
Pseudomonas aeruginosa (PA) is one of the most important causes of healthcare-related infections among Gram-negative bacteria. The best therapeutic approach is controversial, especially for multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains as well as in the setting of most severe patients, such as in the intensive care unit (ICU). Areas covered: This article addresses several points. First, the main microbiological aspects of PA, focusing on its wide array of resistance mechanisms. Second, risk factors and the worse outcome linked to MDR-PA infection...
August 18, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28761575/chemical-stability-of-ceftolozane-tazobactam-in-polyvinylchloride-bags-and-elastomeric-pumps
#8
Joseph Terracciano, Elizabeth G Rhee, Jacqueline Walsh
BACKGROUND: Elastomeric pumps are often used to administer intravenous antibiotics in the outpatient setting, but effective infusion requires that the drug remain stable in solution throughout the procedure. OBJECTIVE: To determine the chemical stability of ceftolozane/tazobactam when reconstituted and stored over an extended time in the AccuFlo (EMED Technologies, El Dorado Hills, California) and I-Flow Homepump Eclipse (Halyard, Alpharetta, Georgia) elastomeric pumps compared with the results of the label-supporting studies in polyvinylchloride (PVC) bags...
2017: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/28748397/activity-of-the-novel-siderophore-cephalosporin-cefiderocol-against-multidrug-resistant-gram-negative-pathogens
#9
J Dobias, V Dénervaud-Tendon, L Poirel, P Nordmann
The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative isolates collected from hospitals worldwide were tested against cefiderocol and antibiotic comparators (ceftolozane-tazobactam [CT], meropenem [MEM], ceftazidime [CAZ], ceftazidime-avibactam [CZA], colistin [CST], aztreonam [ATM], amikacin [AMK], ciprofloxacin [CIP], cefepime [FEP], and tigecycline [TGC]) for their susceptibility...
July 26, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28739780/multicenter-evaluation-of-ceftazidime-avibactam-and-ceftolozane-tazobactam-inhibitory-activity-against-meropenem-non-susceptible-p-aeruginosa-from-blood-respiratory-tract-and-wounds
#10
Mordechai Grupper, Christina Sutherland, David P Nicolau
The recent escalation of carbapenem-resistant Pseudomonas aeruginosa has been recognized globally and threatens to erode the widespread clinical utility of this class of compounds for this prevalent healthcare associate pathogen. Herein, we compared the in-vitro inhibitory activity of ceftazidime-avibactam and ceftolozane-tazobactam against 290 meropenem non-susceptible Pseudomonas aeruginosa non-duplicate clinical isolates from 34 US hospitals using reference broth microdilution methods. Ceftazidime-avibactam and ceftolozane-tazobactam were active, with ceftolozane-tazobactam having significantly higher inhibitory activity than ceftazidime-avibactam...
July 24, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28735046/ceftolozane-tazobactam-activity-against-drug-resistant-enterobacteriaceae-and-pseudomonas-aeruginosa-causing-healthcare-associated-infections-in-australia-and-new-zealand-report-from-an-antimicrobial-surveillance-program-2013-2015
#11
M A Pfaller, D Shortridge, H S Sader, R K Flamm, M Castanheira
OBJECTIVES: To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection. METHODS: A total of 1459 gram-negative organisms (440 P. aeruginosa and 1019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria...
September 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28705666/in-vitro-activity-of-ceftolozane-tazobactam-against-pseudomonas-aeruginosa-and-enterobacteriaceae-isolates-recovered-from-hospitalized-patients-in-germany
#12
Harald Seifert, Barbara Körber-Irrgang, Michael Kresken
To evaluate the activity of ceftolozane/tazobactam in comparison with other broad-spectrum antimicrobials against Pseudomonas aeruginosa and Enterobacteriaceae, 497 non-duplicate P. aeruginosa and 802 Enterobacteriaceae clinical isolates were consecutively collected during the period from September 2014 to April 2015 from patients in Germany with bloodstream, lower respiratory tract, intraabdominal or urinary tract infections. Antimicrobial susceptibility testing was performed by broth microdilution. Results were interpreted according to EUCAST criteria...
July 10, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28689923/in-vitro-activity-of-ceftolozane-tazobactam-in-combination-with-other-classes-of-antibacterial-agents
#13
Cédric Jacqueline, Karen Howland, Laurent Chesnel
OBJECTIVES: Combination antibiotic therapy has been used successfully to treat some patients with bacterial infections. However, although certain combinations may result in beneficial synergistic activity, others may produce antagonistic effects resulting in poor treatment outcomes. Ceftolozane/tazobactam is an antibacterial agent with potent activity against Pseudomonas aeruginosa and many other Gram-negative pathogens, including extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae...
September 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28674059/in-vivo-emergence-of-resistance-to-novel-cephalosporin-%C3%AE-lactamase-inhibitor-combinations-through-the-duplication-of-amino-acid-d149-from-oxa-2-%C3%AE-lactamase-oxa-539-in-sequence-type-235-pseudomonas-aeruginosa
#14
Pablo A Fraile-Ribot, Xavier Mulet, Gabriel Cabot, Ester Del Barrio-Tofiño, Carlos Juan, José L Pérez, Antonio Oliver
Resistance development to novel cephalosporin-β-lactamase inhibitor combinations during ceftazidime treatment of a surgical infection by Pseudomonas aeruginosa was investigated. Both initial (97C2) and final (98G1) isolates belonged to the high-risk clone sequence type (ST) 235 and were resistant to carbapenems (oprD), fluoroquinolones (GyrA-T83I, ParC-S87L), and aminoglycosides (aacA7/aacA8/aadA6). 98G1 also showed resistance to ceftazidime, ceftazidime-avibactam, and ceftolozane-tazobactam. Sequencing identified blaOXA-2 in 97C2, but 98G1 contained a 3-bp insertion leading to the duplication of the key residue D149 (designated OXA-539)...
September 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28674053/in-vitro-activity-of-ceftolozane-tazobactam-and-other-antimicrobial-agents-against-burkholderia-cepacia-complex-and-burkholderia-gladioli
#15
Dale M Mazer, Carol Young, Linda M Kalikin, Theodore Spilker, John J LiPuma
We tested the activities of ceftolozane-tazobactam and 13 other antimicrobial agents against 221 strains of Burkholderia cepacia complex and Burkholderia gladioli Most strains (82%) were cultured from persons with cystic fibrosis, and most (85%) were recovered since 2011. The ceftolozane-tazobactam MIC was ≤8 μg/ml for 77% of the strains. However, the MIC range was broad (≤0.5 to >64 μg/ml; MIC50/90, 2/32 μg/ml). Significant differences in susceptibility to some antimicrobial agents were observed between species...
September 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28610832/comparison-of-antimicrobial-activity-between-ceftolozane-tazobactam-and-ceftazidime-avibactam-against-multidrug-resistant-isolates-of-escherichia-coli-klebsiella-pneumoniae-and-pseudomonas-aeruginosa
#16
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza
OBJECTIVE: This study compared the activity of ceftolozane-tazobactam and ceftazidime-avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas aeruginosa, isolated from patients admitted to Cleveland Clinic Abu Dhabi, United Arab Emirates. METHODS: In vitro susceptibility was tested using the Etest strip minimum inhibitory concentration (MIC) method, and PCR was used to characterize the carbapenemase enzymes produced by CRE strains...
June 10, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28575437/successful-treatment-of-post-surgical-osteomyelitis-caused-by-xdr-pseudomonas-aeruginosa-with-ceftolozane-tazobactam-monotherapy
#17
Ivan Gentile, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Riccardo Scotto, Federico De Zottis, Gianfranco Di Renzo, Guglielmo Borgia
No abstract text is available yet for this article.
September 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28532194/cost-effectiveness-of-ceftolozane-tazobactam-plus-metronidazole-compared-with-piperacillin-tazobactam-as-empiric-therapy-for-the-treatment-of-complicated-intra-abdominal-infections-based-on-the-in-vitro-surveillance-of-bacterial-isolates-in-the-uk
#18
Vimalanand Prabhu, Jason Foo, Harblas Ahir, Eric Sarpong, Sanjay Merchant
AIMS: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently. A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in UK hospitals...
June 8, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28520867/activity-of-ceftolozane-tazobactam-against-surveillance-and-problem-enterobacteriaceae-pseudomonas-aeruginosa-and-non-fermenters-from-the-british-isles
#19
David M Livermore, Shazad Mushtaq, Daniele Meunier, Katie L Hopkins, Robert Hill, Rachael Adkin, Aiysha Chaudhry, Rachel Pike, Peter Staves, Neil Woodford
Background: We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 and against 'problem' isolates sent to the UK national reference laboratory from July 2015, when routine testing began. Methods: Susceptibility testing was by BSAC agar dilution with resistance mechanisms identified by PCR and interpretive reading. Results: Data were reviewed for 6080 BSAC surveillance isolates and 5473 referred organisms...
August 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28503325/ceftolozane-tazobactam-for-febrile-uti-due-to-multidrug-resistant-pseudomonas-aeruginosa-in-a-patient-with-neurogenic-bladder
#20
Aurélien Dinh, Benjamin Davido, Ruxandra Calin, Julie Paquereau, Clara Duran, Frédérique Bouchand, Véronique Phé, Emmanuel Chartier-Kastler, Martin Rottman, Jérôme Salomon, Patrick Plésiat, Anaïs Potron
INTRODUCTION: Urinary tract infections (UTI) are a major public health problem among spinal cord injury (SCI) patients. They frequently involve multidrug-resistant (MDR) bacteria. Ceftolozane/tazobactam (C/T) is a novel antibiotic combination approved for complicated intra-abdominal and UTI caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for complicated febrile UTI occurring among SCI patients with neurogenic bladder due to MDR Pseudomonas aeruginosa (PSA)...
2017: Spinal Cord Series and Cases
keyword
keyword
56087
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"